Transverse Myelitis

Disclaimer: This document provides comprehensive medical information for educational and reference purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always use their independent medical judgment in the context of individual patient circumstances, considering all available clinical data and patient preferences. Treatment decisions should be made in consultation with the patient and based on the most current evidence and clinical guidelines.

Overview

• Definition: Transverse myelitis (TM) is an acute or subacute inflammatory disorder of the spinal cord that impairs the transmission of neural impulses up and down the spinal cord. It is characterized by motor weakness, sensory disturbances, and autonomic dysfunction, typically below a well-defined sensory level. The term "transverse" implies that the inflammation affects the entire cross-section of the spinal cord at the level of the lesion.
• Epidemiology:
  • Incidence: Estimated at 1 to 4 new cases per million people per year.
  • Prevalence: Approximately 30,000 cases in the United States.
  • Age: Occurs at any age, with a bimodal peak typically between ages 10-19 years and 30-39 years.
  • Gender: Affects males and females equally, although some studies suggest a slight female predominance in certain subtypes (e.g., NMOSD-related TM).
  • Ethnicity: No significant ethnic predilection identified.
• Classification: TM can be classified based on etiology and clinical characteristics:
  • Idiopathic Transverse Myelitis: Approximately 30-50% of cases are considered idiopathic, meaning no clear underlying cause is identified despite thorough investigation.
  • Secondary Transverse Myelitis: TM can be a manifestation of various systemic diseases or conditions:
    • Demyelinating Diseases:
      • Multiple Sclerosis (MS): A transverse myelitis attack can be the first presentation of MS, or occur during the disease course. Spinal cord lesions in MS are typically partial, peripherally located, and involve <3 vertebral segments.
      • Neuromyelitis Optica Spectrum Disorder (NMOSD): Often presents with longitudinally extensive transverse myelitis (LETM), typically spanning ≥3 vertebral segments, and frequently accompanied by optic neuritis. Associated with antibodies to Aquaporin-4 (AQP4-IgG).
      • Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Can cause TM, often LETM, similar to NMOSD, but also short lesions. May also involve brainstem, optic nerves, and cerebral cortex. Associated with antibodies to Myelin Oligodendrocyte Glycoprotein (MOG-IgG).
    • Post-infectious/Para-infectious: Occurs days to weeks after a viral (e.g., influenza, enterovirus, HIV, HSV, VZV, CMV, EBV) or bacterial infection (e.g., Mycoplasma pneumoniae, Borrelia burgdorferi, Syphilis). Proposed immune-mediated mechanism.
    • Systemic Autoimmune Diseases: Systemic lupus erythematosus (SLE), Sjögren's syndrome, Behçet's disease, sarcoidosis, vasculitis (e.g., ANCA-associated vasculitis).
    • Paraneoplastic Syndromes: Rarely, TM can be a paraneoplastic manifestation of certain cancers.
    • Vascular: Spinal cord infarction (uncommon for TM presentation, but can mimic).
    • Nutritional: B12 deficiency (subacute combined degeneration) can mimic, but is not inflammatory.

Pathophysiology

• Mechanism: The underlying mechanism involves an immune-mediated inflammatory attack on the spinal cord. This leads to demyelination (destruction of the myelin sheath that insulates nerve fibers) and, in more severe cases, axonal injury (damage to the nerve fibers themselves).
  • Cellular and Humoral Immunity: Both T-cells and B-cells play roles. Activated T-lymphocytes cross the blood-spinal cord barrier and initiate an inflammatory cascade. B-cells produce antibodies (e.g., AQP4-IgG, MOG-IgG) that target specific antigens on astrocytes or oligodendrocytes, leading to direct tissue damage.
  • Inflammatory Mediators: Cytokines (e.g., TNF-alpha, interleukins), chemokines, and reactive oxygen species contribute to local inflammation, edema, and neuronal dysfunction/damage.
  • Vascular Involvement: Inflammation can also affect blood vessels within the spinal cord, leading to ischemia and further damage.
• Risk Factors:
  • Recent Infections: Viral or bacterial infections preceding symptom onset (common in post-infectious TM).
  • Autoimmune Predisposition: Personal or family history of autoimmune diseases.
  • Specific Antibodies: Presence of AQP4-IgG or MOG-IgG antibodies significantly increases the risk of recurrent attacks and specific associated diseases (NMOSD, MOGAD).
  • Genetic Factors: While no single gene is identified for idiopathic TM, certain HLA types may confer susceptibility to related autoimmune conditions.
  • Vaccinations: A temporal association with certain vaccinations has been reported, but a causal link is not definitively established and is rare.
• Protective Factors: No specific protective factors are known for preventing the initial occurrence of idiopathic TM. For secondary forms, aggressive management of underlying autoimmune conditions may reduce relapse risk.

Clinical Presentation

Signs and Symptoms

Onset of symptoms is typically acute to subacute, progressing over hours to days (up to 4 weeks). - Cardinal Features: * Motor Weakness: The most common symptom, present in over 90% of patients. Ranges from mild paraparesis (weakness in legs) to complete flaccid paraplegia or quadriplegia depending on the level and severity of the lesion. Initial flaccidity may evolve to spasticity over days to weeks. * Sensory Disturbances: Present in nearly all patients. Includes numbness, paresthesias (tingling, pins and needles), dysesthesias (unpleasant abnormal sensations), or pain. A distinct "sensory level" (a horizontal line on the trunk or limbs below which sensation is altered or absent) is characteristic and aids in localizing the lesion. Band-like sensation around the trunk is common. * Autonomic Dysfunction: Present in up to 90% of patients. * Bladder dysfunction: Urinary urgency, frequency, hesitancy, retention (most common), or incontinence. * Bowel dysfunction: Constipation, fecal incontinence. * Sexual dysfunction. * Autonomic dysregulation: Orthostatic hypotension, sweating abnormalities, temperature dysregulation. - Early Signs: * Back pain (localized at the level of the lesion or radicular pain radiating down a limb) is common (up to 50% of cases) and often an initial symptom. * Leg weakness or heaviness. * Paresthesias or numbness in feet/legs ascending upwards. * Urinary urgency or difficulty initiating urination. - Advanced Signs: * Rapid progression to severe paraplegia or quadriplegia. * Loss of all sensation below the lesion. * Complete bladder and bowel retention. * Respiratory compromise (if the lesion involves cervical segments C3-C5, affecting diaphragm innervation). * Profound autonomic dysregulation. - Atypical Presentations: * Brown-Séquard Syndrome: Hemisection of the spinal cord, leading to ipsilateral motor weakness and proprioceptive loss, and contralateral pain and temperature loss below the lesion. Uncommon in typical TM. * Ascending or Descending Myelitis: Symptoms spreading upwards or downwards after initial onset. * Recurrent Transverse Myelitis: Suggests an underlying condition like MS, NMOSD, or MOGAD, rather than idiopathic TM.

Physical Examination

A thorough neurological examination is crucial to localize the spinal cord lesion and assess its severity. - Inspection: * General assessment: Observe for signs of distress, respiratory effort. * Posture and gait: May reveal weakness, spasticity, or ataxia. * Skin: Check for signs of autonomic dysfunction (e.g., sweating changes) or pressure ulcers if immobility is prolonged. - Palpation: * Spinal palpation: May reveal tenderness at the level of the lesion, although this is uncommon. * Bladder palpation: Check for distended bladder if retention is suspected. - Special Tests: * Motor Examination: * Strength: Assess strength in all major muscle groups (MRC scale 0-5). Look for weakness below the level of the lesion. * Tone: Initially flaccid, then develops into spasticity and hypertonia over days to weeks. * Reflexes: Areflexia or hyporeflexia in the acute phase due to spinal shock below the lesion; later hyperreflexia, clonus, and positive Babinski sign as spinal shock resolves and upper motor neuron signs emerge. * Sensory Examination: * Pinprick and Light Touch: To define the sensory level. This is the most critical part of the sensory exam for TM. * Vibration and Proprioception: Assess posterior column function. Often impaired. * Temperature: Less commonly tested, but follows pain pathway. * Autonomic Examination: * Anal Tone: Decreased anal sphincter tone is common. * Bulbocavernosus Reflex: Often absent. * Orthostatic Blood Pressure: Check for autonomic dysregulation.

Diagnostic Approach

The diagnosis of TM is primarily clinical, supported by imaging and laboratory findings, and requires exclusion of other causes of myelopathy.

History Taking

• Key Questions:
  • Onset and Progression: Acute vs. subacute (hours to days vs. weeks)? Monophasic vs. recurrent?
  • Symptom Details: Specific motor weakness (e.g., paraparesis, quadriparesis), sensory deficits (numbness, tingling, pain, sensory level), and autonomic dysfunction (bladder/bowel/sexual).
  • Associated Symptoms: Back pain, Lhermitte's sign (electric shock sensation down spine with neck flexion), optic neuritis, brainstem symptoms.
  • Preceding Events: Recent infections (viral, bacterial), vaccinations, travel history, tick bites.
  • Past Medical History: History of autoimmune diseases (e.g., SLE, Sjögren's, MS), cancer, or other neurological conditions.
  • Family History: Of autoimmune or neurological diseases.
  • Medications: Including any immunosuppressants.
• Red Flags:
  • Rapidly progressing severe weakness/paralysis: Suggests aggressive inflammation or a compressive lesion.
  • Respiratory distress/insufficiency: Implies high cervical cord involvement requiring urgent airway management.
  • Signs of cauda equina syndrome (e.g., severe radicular pain, saddle anesthesia, severe bowel/bladder dysfunction, lower motor neuron weakness): Necessitates urgent exclusion of compressive lesions.
  • Fever or signs of systemic infection: May indicate an infectious myelitis or abscess.

Laboratory Tests

Laboratory investigations are essential to identify underlying causes and differentiate TM from other myelopathies. - First-Line: * Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP): To assess general health, rule out electrolyte abnormalities. * Inflammatory Markers: Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) – may be elevated, indicating systemic inflammation. * Autoimmune Screening: * Antinuclear Antibody (ANA), Extractable Nuclear Antigens (ENA) panel (anti-Ro/SSA, anti-La/SSB, anti-RNP, anti-Sm, anti-Jo-1): For systemic autoimmune diseases (e.g., SLE, Sjögren's syndrome). * Antineutrophil Cytoplasmic Antibodies (ANCA): For vasculitis. * Anti-phospholipid antibodies: For antiphospholipid syndrome. * Infectious Workup: * Lyme serology (if endemic area). * Syphilis serology (RPR/VDRL with FTA-ABS confirmation). * HIV testing. * Mycoplasma pneumoniae serology. * Viral serologies for HSV, VZV, CMV, EBV, enterovirus, West Nile virus (based on clinical suspicion). - Confirmatory (Specific Antibody Testing): These are critical for differentiating TM from other demyelinating conditions with distinct treatment and prognosis. * Aquaporin-4 IgG (AQP4-IgG) antibody: Assays (cell-based assay preferred due to higher sensitivity/specificity) for NMOSD. Present in 70-80% of NMOSD cases. * Myelin Oligodendrocyte Glycoprotein IgG (MOG-IgG) antibody: Cell-based assay for MOGAD. Essential for diagnosis as MOGAD can mimic MS or NMOSD. - Cerebrospinal Fluid (CSF) Analysis: Obtained via lumbar puncture. * Cell count and differential: Pleocytosis (elevated white blood cell count, typically mononuclear, but can be neutrophilic in early/severe cases) is common (50-70% of cases), usually <200 cells/µL. Higher counts may suggest infectious causes. * Protein: Mildly elevated protein (50-100 mg/dL) is common. Markedly elevated protein suggests other causes (e.g., Guillain-Barré syndrome, compressive lesion). * Glucose: Usually normal. * Oligoclonal Bands (OCBs): May be present in 10-20% of TM cases. More common in MS (~90%), less so in NMOSD (~10-30%) or MOGAD (rare). Presence of OCBs increases suspicion for underlying MS. * IgG Index: May be elevated, indicating intrathecal IgG synthesis. * CSF Specific Antibody Testing: AQP4-IgG and MOG-IgG testing can also be performed on CSF, though serum is often sufficient and preferred. * Infectious Studies on CSF: PCR for viruses (HSV, VZV, CMV, EBV, enterovirus), bacterial culture, fungal studies (if suspected).

Imaging

Imaging is paramount to confirm spinal cord involvement, rule out compressive lesions, and differentiate TM subtypes. - Recommended: * Spinal Magnetic Resonance Imaging (MRI) with and without gadolinium contrast: * Protocol: Needs to cover the entire spinal cord (cervical, thoracic, and conus medullaris) and include T1, T2, FLAIR, STIR, and post-contrast T1 sequences. * Findings: * T2 Hyperintensity: Areas of increased signal intensity within the spinal cord, indicating edema, inflammation, or demyelination. * Gadolinium Enhancement: Suggests active inflammation and blood-spinal cord barrier breakdown. * Location: Typically central gray matter or posterior columns. * Extent: Crucial for differentiation. * Longitudinally Extensive Transverse Myelitis (LETM): Lesion spanning ≥3 vertebral segments. Highly suggestive of NMOSD or MOGAD. Less common in MS. * Short Segment Lesions: Typically <2 vertebral segments. More common in MS. * Transverse Extent: Involvement of >2/3 of the cord's cross-sectional area suggests NMOSD/MOGAD. Partial involvement is more common in MS. * Swelling: Cord enlargement or swelling may be present in acute phases. * Purpose: Essential to rule out compressive lesions (e.g., tumor, disc herniation, epidural abscess, hematoma) which require urgent surgical intervention. * Brain MRI with and without gadolinium contrast: * Purpose: To evaluate for concurrent brain lesions that may suggest MS (e.g., periventricular, juxtacortical, infratentorial, or corpus callosum lesions) or other CNS inflammatory diseases. Abnormal brain MRI significantly influences prognosis and long-term management strategies, especially regarding MS.

Management

Acute TM is a neurological emergency requiring prompt diagnosis and aggressive immunomodulatory treatment to minimize neurological damage and improve functional outcomes.

Acute Management

Initiated as soon as TM is suspected and compressive causes are ruled out. - Immediate (First-hour interventions): * Airway, Breathing, Circulation (ABC) assessment: Especially if high cervical lesion suspected (C3-C5), as respiratory muscle weakness can lead to respiratory failure. May require intubation and mechanical ventilation. * Cardiac monitoring: For autonomic dysregulation (bradycardia, arrhythmias). * Bladder management: Insert indwelling urinary catheter if retention is present. * Pain management: For neuropathic pain or back pain. - Stabilization (Early management priorities): * High-dose Intravenous Corticosteroids: The cornerstone of acute TM treatment. * Agent: Methylprednisolone is typically used. * Dosage: 1000 mg IV daily for 3 to 7 days. * Mechanism: Reduces inflammation and edema in the spinal cord. * Monitoring: Blood glucose, electrolytes, blood pressure. Consider proton pump inhibitor for gastric protection. - Emergency (Crisis Management): * Plasma Exchange (PLEX) / Plasmapheresis: * Indication: Considered for patients who show no improvement or worsen after 3-5 days of high-dose IV corticosteroids. Also used as first-line for severe cases of AQP4-IgG positive NMOSD. * Procedure: Typically 5-7 exchanges over 7-14 days. Each exchange replaces plasma with albumin or fresh frozen plasma. * Mechanism: Removes circulating antibodies, inflammatory mediators, and other harmful substances. * Efficacy: Shown to be effective in patients with moderate to severe TM, improving outcomes, especially if initiated early. * Intravenous Immunoglobulin (IVIG): * Indication: Less evidence for efficacy compared to PLEX for TM, but may be considered as an alternative if PLEX is contraindicated or unavailable, or in pediatric cases. * Dosage: Typically 0.4 g/kg/day for 5 days (total 2 g/kg). * Mechanism: Modulates the immune system through various mechanisms, including blocking Fc receptors, neutralizing pathogenic antibodies, and modulating cytokine production.

Chronic Management

Focuses on preventing relapses in secondary TM, managing residual symptoms, and rehabilitation. - Pharmacological (Long-term immunosuppression for secondary causes): * For NMOSD (AQP4-IgG positive): Long-term immunosuppression is crucial to prevent relapses. * First-line: Azathioprine (2-3 mg/kg/day orally), Mycophenolate Mofetil (1000-1500 mg orally twice daily), or Rituximab (1000 mg IV every 6 months or 375 mg/m2 weekly for 4 weeks then every 6-12 months). * Newer FDA-approved agents: Eculizumab (anti-C5 antibody), Satralizumab (anti-IL-6 receptor antibody), Inebilizumab (anti-CD19 antibody). These are highly effective but expensive. * For MOGAD (MOG-IgG positive): Long-term immunosuppression is often required due to high relapse rates. * Agents: Rituximab, Azathioprine, Mycophenolate Mofetil, or oral corticosteroids (e.g., prednisone 5-10 mg daily) are commonly used off-label. No FDA-approved disease-modifying therapies specifically for MOGAD yet, but trials are ongoing. * For MS: Patients diagnosed with MS after TM require disease-modifying therapies (DMTs) for MS. The choice of DMT depends on disease activity and patient factors. * Symptomatic Management: * Spasticity: Baclofen (5-20 mg PO 3-4 times daily, titrate), Tizanidine (2-8 mg PO 3 times daily, titrate), gabapentin, clonazepam. Intrathecal baclofen pump for severe, refractory spasticity. Botulinum toxin injections for focal spasticity. * Neuropathic Pain: Gabapentin (300-1200 mg PO 3 times daily), Pregabalin (75-300 mg PO twice daily), Duloxetine (30-60 mg PO daily), Tricyclic Antidepressants (e.g., Amitriptyline 10-100 mg PO at bedtime), Carbamazepine for sharp, shooting pains. * Bladder Dysfunction: * Overactive bladder: Anticholinergics (Oxybutynin 5-15 mg PO daily), Mirabegron. * Urinary retention: Intermittent catheterization. * Bowel Dysfunction: Laxatives, stool softeners, bowel regimens for constipation. * Fatigue: Modafinil, amantadine (limited evidence). * Depression/Anxiety: Antidepressants, anxiolytics, psychological counseling. - Non-pharmacological: * Rehabilitation: Essential for recovery and functional independence. * Physical Therapy: Early initiation for strengthening, range of motion, stretching, gait training, balance, transfer training, and mobility. * Occupational Therapy: Focus on activities of daily living (ADLs), adaptive equipment, home modifications. * Speech Therapy: If bulbar involvement is present. * Psychological Support: Counseling, support groups to address emotional impact, depression, and anxiety. * Nutritional Support: Maintaining adequate nutrition. * Skin Care: Prevention and management of pressure ulcers. * Deep Vein Thrombosis (DVT) Prophylaxis: For immobilized patients (e.g., low-molecular-weight heparin). - Monitoring: * Neurological Status: Regular neurological examinations, functional assessments (e.g., Modified Rankin Scale, Expanded Disability Status Scale - EDSS). * MRI: Follow-up spinal and brain MRIs as clinically indicated (e.g., annually for secondary causes, or if new symptoms occur) to monitor disease activity and identify new lesions. * Laboratory Tests: Periodic blood tests to monitor for side effects of immunosuppressive medications (e.g., CBC, LFTs, renal function), and antibody titers if relevant (e.g., AQP4-IgG).

Treatment Algorithms

• First-Line:
  1. Rule out compressive myelopathy via urgent MRI.
  2. If non-compressive, initiate high-dose IV Methylprednisolone 1000 mg IV daily for 3-7 days.
• Second-Line:
  1. If no or minimal improvement, or worsening after 3-5 days of IV corticosteroids, initiate Plasma Exchange (PLEX). Typically 5-7 exchanges over 7-14 days.
  2. Alternatively, or if PLEX is contraindicated/unavailable, IVIG (0.4 g/kg/day for 5 days) can be considered, especially in pediatric cases or milder forms.
• Refractory Cases (Acute Phase):
  • Consider Cyclophosphamide for severe, refractory cases not responding to steroids and PLEX, particularly in autoimmune-related TM.
• Long-term Prevention of Relapses (for secondary TM):
  • NMOSD (AQP4-IgG positive): Initiate long-term immunosuppression (Rituximab, Azathioprine, Mycophenolate Mofetil, or FDA-approved agents like Eculizumab, Satralizumab, Inebilizumab).
  • MOGAD (MOG-IgG positive): Consider long-term immunosuppression (e.g., Rituximab, Azathioprine, Mycophenolate Mofetil, low-dose oral corticosteroids) due to high relapse risk.
  • MS: Start appropriate disease-modifying therapy for MS.
  • Idiopathic TM: No long-term immunomodulation is typically given after a single attack, but close monitoring for signs of evolving MS/NMOSD/MOGAD is required.

Complications

Complications are common and can significantly impact long-term quality of life. - Common: * Chronic Pain: Neuropathic pain and musculoskeletal pain due to spasticity or immobility. * Spasticity: Persistent muscle stiffness and spasms, leading to contractures and gait difficulties. * Bladder and Bowel Dysfunction: Chronic urinary retention, incontinence, recurrent UTIs, constipation, fecal incontinence. * Sexual Dysfunction: Common in both men and women. * Depression and Anxiety: Psychological impact of chronic illness and disability. * Fatigue: Debilitating symptom, often out of proportion to physical exertion. - Serious: * Respiratory Failure: If high cervical cord (C3-C5) is involved, affecting diaphragmatic innervation. Requires mechanical ventilation. * Aspiration Pneumonia: Due to bulbar weakness or immobility. * Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Due to immobility and hypercoagulability. * Pressure Ulcers (Bedsores): Due to prolonged immobility and sensory loss. * Autonomic Dysreflexia: Life-threatening condition in patients with spinal cord injury above T6, triggered by noxious stimuli below the level of injury (e.g., full bladder, bowel impaction). Characterized by sudden severe hypertension, bradycardia, headache, sweating above lesion, and pallor below. * Recurrent UTIs and Urosepsis: Due to neurogenic bladder. - Long-term: * Persistent Neurological Deficits: Varying degrees of motor, sensory, and autonomic impairment. * Significant Disability: Many patients require assistive devices (e.g., walkers, wheelchairs) and assistance with ADLs. * Increased Risk of Other Autoimmune Diseases: For those with idiopathic TM, there is a small risk of developing MS or other autoimmune conditions later.

Prognosis

The prognosis of TM is variable and depends on several factors. - Factors Affecting Outcome: * Severity at Nadir: The greater the severity of neurological deficits at their worst point (nadir), the poorer the prognosis. Complete motor and sensory loss at nadir predicts a worse outcome. * Rate of Progression: Rapid progression to maximal deficit (within hours to a few days) is generally associated with a poorer prognosis than a more gradual progression. * Presence of Back Pain: The presence of back pain at onset has been associated with a better prognosis, possibly indicating a less severe inflammatory insult. * Spinal MRI Findings: * LETM (≥3 vertebral segments) and extensive cord swelling often correlate with worse outcomes, especially in NMOSD. * Presence of gadolinium enhancement suggests active inflammation but does not reliably predict outcome. * Absence of AQP4-IgG and MOG-IgG and normal brain MRI suggests idiopathic TM, which generally has a better prognosis than NMOSD/MOGAD, though recurrence is still possible. * Age: Extreme ages (very young or very old) may have worse outcomes. * Treatment Responsiveness: Early initiation of corticosteroids and subsequent PLEX (if needed) improves outcomes. - Survival: The mortality rate directly attributable to TM is low, typically related to complications such as respiratory failure, pulmonary embolism, or sepsis. - Quality of Life: Functional outcomes are highly variable: * Approximately one-third of patients experience good recovery with minimal or no residual deficits. * Approximately one-third have moderate disability, requiring assistive devices (e.g., cane, walker) but remain ambulatory. * Approximately one-third have severe disability, requiring a wheelchair and significant assistance with ADLs due to severe motor, sensory, or autonomic dysfunction. * Most recovery occurs within the first 3-6 months, but improvement can continue for up to 1-2 years. Little improvement is expected after 2 years.

Prevention

• Primary Prevention:
  • There are no known primary prevention strategies for idiopathic TM as its etiology is unclear.
  • For secondary TM, managing underlying autoimmune conditions (e.g., SLE, Sjögren's syndrome) may reduce the risk of TM as a complication.
• Secondary Prevention:
  • Early Diagnosis and Aggressive Treatment: Prompt recognition of TM symptoms and immediate initiation of high-dose corticosteroids, followed by PLEX if indicated, are crucial to limit acute damage and improve recovery.
  • Long-term Immunosuppression: For patients diagnosed with NMOSD or MOGAD, continuous long-term immunosuppressive therapy is critical to prevent future relapses, which can cause cumulative neurological damage.
• Tertiary Prevention:
  • Comprehensive Rehabilitation: To minimize long-term disability, improve functional independence, and enhance quality of life.
  • Management of Complications: Proactive management of bladder/bowel dysfunction, spasticity, pain, and skin integrity to prevent serious complications (e.g., UTIs, pressure ulcers, contractures).
  • Psychological Support: To address the mental health impact of living with a chronic condition.

Special Populations

• Pediatric:
  • Prevalence: Accounts for 20% of TM cases.
  • Etiology: More commonly associated with a preceding infection (post-infectious TM).
  • Presentation: Similar to adults, but often presents with a more acute and severe course.
  • Diagnosis: Spinal MRI, CSF analysis, and antibody testing (AQP4-IgG, MOG-IgG) are essential.
  • Management: High-dose IV corticosteroids are first-line. PLEX is effective. IVIG may be considered more readily in children. Long-term outcomes can be good, but a significant proportion have residual deficits. Higher incidence of MOGAD in pediatric TM.
• Geriatric:
  • Diagnosis: May be challenging due to comorbid conditions and atypical presentations.
  • Management: Corticosteroid use requires careful monitoring for side effects (e.g., hyperglycemia, delirium, increased infection risk, bone density loss). Polypharmacy and underlying health status must be considered for all treatments.
  • Prognosis: Older age is generally associated with poorer functional recovery.
• Pregnancy:
  • Diagnosis: MRI is generally safe during pregnancy (avoid gadolinium in the first trimester unless absolutely necessary).
  • Management: High-dose IV corticosteroids are generally considered safe in pregnancy, particularly after the first trimester. PLEX is also considered safe. Long-term immunosuppressants for NMOSD/MOGAD require careful consideration of fetal risks (e.g., Azathioprine generally considered safer than Mycophenolate Mofetil).
  • Relapse Risk: Pregnancy itself can influence relapse rates in underlying conditions like MS or NMOSD.
• Comorbidities:
  • Diabetes: Close monitoring of blood glucose during corticosteroid therapy. Insulin may be required temporarily.
  • Cardiovascular Disease: Autonomic dysfunction can exacerbate orthostatic hypotension or cause dysrhythmias, requiring careful monitoring and management.
  • Renal Impairment: Dose adjustments for certain medications, careful fluid management for PLEX.
  • Immunocompromised States: Increased risk of infection, requiring proactive infection surveillance and prophylaxis.

Clinical Pearls

• Diagnostic:
  • Always exclude a compressive lesion: Spinal MRI is paramount and should be performed urgently to rule out conditions requiring surgical intervention. Imaging the entire spine (cervical, thoracic, lumbar) is crucial.
  • Do a brain MRI: To rule out brain lesions suggesting MS, which significantly impacts long-term management and prognosis.
  • Test for AQP4-IgG and MOG-IgG antibodies: These are essential to differentiate between idiopathic TM, NMOSD, and MOGAD, which have distinct prognoses and require different long-term therapies. Serum is preferred, but CSF can also be tested.
  • Perform CSF analysis: To assess for pleocytosis, protein elevation, and oligoclonal bands.
  • A clear sensory level: Is a highly suggestive clinical finding for TM.
• Treatment:
  • Time is spine: Early and aggressive immunotherapy (high-dose IV corticosteroids) is critical for improving outcomes.
  • Don't hesitate to use PLEX: If there's no improvement or worsening after 3-5 days of steroids, PLEX is a highly effective second-line therapy and should be initiated promptly.
  • Long-term immunosuppression is key for NMOSD/MOGAD: Do not discharge patients with these diagnoses without a clear long-term relapse prevention plan.
  • Rehabilitation is as important as pharmacotherapy: Early and intensive rehabilitation (physical, occupational therapy) is crucial for maximizing functional recovery.
• Pitfalls:
  • Misdiagnosis: Mistaking TM for a functional disorder or psychological condition, leading to delayed treatment.
  • Missing a compressive lesion: Failing to get an urgent spinal MRI, which can lead to permanent neurological damage if a surgical emergency is overlooked.
  • Not testing for specific antibodies (AQP4-IgG, MOG-IgG): This oversight leads to misclassification of the disease, potentially missing a diagnosis of NMOSD or MOGAD, and thus failing to implement appropriate long-term preventative therapies.
  • Delaying PLEX: Waiting too long to initiate PLEX after steroid failure can reduce its effectiveness.
  • Underestimating the long-term impact: TM can have profound and lasting effects on physical function and mental health; comprehensive care involves addressing these.

Recent Updates

• Guidelines:
  • International Consensus Diagnostic Criteria for Transverse Myelitis (2022): The Transverse Myelitis Association (TMA) and an international panel of experts published updated diagnostic criteria, emphasizing the importance of excluding mimicking conditions and differentiating between idiopathic TM, MS-associated TM, NMOSD-associated TM, and MOGAD-associated TM. These criteria guide comprehensive evaluation.
• Evidence:
  • New Therapies for NMOSD: Several new targeted therapies have received FDA approval, demonstrating significant efficacy in reducing relapse rates in AQP4-IgG positive NMOSD. These include Eculizumab (anti-C5 complement), Satralizumab (anti-IL-6 receptor), and Inebilizumab (anti-CD19 B-cell depletor). Their availability offers more treatment options with improved outcomes for NMOSD patients.
  • MOGAD as a Distinct Entity: Increasing recognition of MOGAD as a separate clinical entity from MS and NMOSD, with specific clinical phenotypes and treatment responses. Research continues on optimal long-term immunosuppression for MOGAD, with Rituximab, mycophenolate mofetil, and azathioprine commonly used off-label.
  • Rehabilitation Advances: Continued research into neurorehabilitation strategies, including robot-assisted therapy and functional electrical stimulation, shows promise for improving motor recovery.
• Controversies:
  • Optimal Duration of Steroid Treatment: While 3-7 days is standard, optimal duration for specific clinical scenarios is debated.
  • Role of IVIG vs. PLEX: The exact comparative efficacy and indications for IVIG versus PLEX in acute TM remain an area of ongoing research, though PLEX is generally favored for severe cases unresponsive to steroids.
  • Long-term management of idiopathic TM: The decision to offer long-term immunomodulation for recurrent "idiopathic" TM remains challenging, often prompting re-evaluation for evolving underlying conditions.

Key References

• Guidelines:
  • International Consensus Diagnostic Criteria for Transverse Myelitis. Published by the Transverse Myelitis Association and an international expert panel (e.g., Scott et al., Neurology 2022).
  • Consensus Recommendations for the Management of Neuromyelitis Optica Spectrum Disorder (NMOSD). International Panel for NMO Diagnosis (IPND) (e.g., Wingerchuk et al., Neurology 2015 and subsequent updates).
  • Guidelines for the diagnosis and treatment of MOGAD (still evolving, often expert consensus papers).
• Studies:
  • Transverse Myelitis: A Review of the Current Literature and Clinical Practice. (e.g., West et al., Semin Neurol 2017).
  • Specific clinical trials for new NMOSD therapies (e.g., PREVENT for Eculizumab, N-MOmentum for Satralizumab, N-MOmentum for Inebilizumab).
• Reviews:
  • Transverse Myelitis: A Neurological Emergency. (e.g., Krishnan and Kaplan, Lancet Neurol 2016).
  • Demyelinating Myelitis: Updates on Classification, Pathophysiology, and Treatment. (e.g., Jarius and Wildemann, CNS Drugs 2018).
  • Comprehensive reviews from major medical journals and clinical reference platforms (e.g., UpToDate, Medscape, NEJM reviews).